|Articles|August 31, 2016

Supplements and Featured Publications

  • Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldost
  • Volume 22
  • Issue 11

eAppendix

Download PDF: eAppendix

Articles in this issue

over 9 years ago

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors

over 9 years ago

Participating Faculty

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care
AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text